At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease. The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research, however, shows that dementia is linked to an array of risk factors, suggesting that some form of a combination therapy is likely to be more effective. But the factors involved also vary among individuals, and a one-combination-therapy-that-fits-all approach is unsuitable. Muses Labs reports that it has found a way to address these issues simultaneously in each individual patient. MEND Protocol is a multi-step cognitive evaluation process, that uses advanced data processing technology to first assess which risk factors are present in an individual. According to the company, more than 50 drivers of cognitive decline exist, of which the top 12 are low thyroid hormone levels, high homocysteine levels, bad diet, insulin resistance, ApoE4, imbalance in metals, stress, depression, elevated blood fats, low exercise, poor sleep, and inflammation. An initial examination, therefore, includes a genetic analysis, medical history, and a lifestyle analysis in addition to laboratory test and cognitive screenings. Taking these and additional risk factors into account, the Muses software then uses advanced algorithms to propose a treatment plan that can easily be adapted by a physician. “Unlike drugs that address a single issue, our evidence-based combination approach targets the 50-plus known causes of cognitive decline that often exist simultaneously,” Vik Chandra, Muses Labs CEO, told Alzheimer’s News Today.